Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo Settles Lawsuit over Evoxac Patent with Apotex
August 16, 2010
- Japan PASS Interim Results for ADVATE Presented
August 16, 2010
- Takeda: Sales, Profits Down due to Lansoprazole Patent Expiration
August 16, 2010
- Fuso: Net Loss despite Increases in Sales
August 16, 2010
- Flu Vaccine Suppliers to Buy Back Med Institutions' Stocks at Their Expense
August 16, 2010
- 2,746 Welfare Recipients Receive Psychotropics from Multiple Med Institutions
August 16, 2010
- Daiichi Sankyo: Olmetec Drives Business
August 16, 2010
- Zeria: Overseas Sales Ratio Up to 13.2% with Addition of Tillotts
August 16, 2010
- AnGes MG Obtains Patent for HFG Gene Therapy for PD in the US
August 16, 2010
- JGA Fails to Achieve No-Shortage Goal in FY2009
August 16, 2010
- Astellas: Patent Expiration Hits Business
August 16, 2010
- ASKA: Seltouch Boosts Sales
August 16, 2010
- Market for Insomnia Treatments to Expand to US$1 Bil. by 2019 in Japan: Datamonitor
August 16, 2010
- Taiyo Yakuhin Posts Measures to Improve Manufacturing Practice on Its Website
August 16, 2010
- Eisai: Sales Up 5% Driven by Good Sales of Aricept
August 16, 2010
- Seikagaku: Sales Remain Virtually Unchanged
August 16, 2010
- Sales of Ethical Drugs Up 2.3% in June: Crecon Report
August 16, 2010
- ARQ 197 to Enter PIII for NSCLC: Daiichi Sankyo, ArQule
August 16, 2010
- MTPC: Sales, Profits Up despite Biz Suspension
August 16, 2010
- JCR Pharmaceuticals: Upfront Payment from GSK Boosts Sales
August 16, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…